Back

Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals

Zhang, J.; Qu, X.

2020-06-14 infectious diseases
10.1101/2020.06.12.20129460 medRxiv
Show abstract

Seroconversion appeared early after COVID-19 onset, and convalescent sera therapy benefit some critical patients. However, neutralizing antibody (nAb) in convalescents is largely unknown. We found that 97.01% (65/67) of COVID-19 convalescents maintained IgG antibodies with high binding and avidity to SARS-CoV-2 spike subunits S1 and S2, and 95.52% (64/67) had neutralization activity against SARS-CoV-2 pesudovirus, one month after discharge (median ID50, 2.75; IQR, 2.34-3.08). Some sera exhibited cross-neutralization against SARS-CoV (76.12%), MERS-CoV (17.91%), or both (10.45%). Interestingly, individuals recovered from severe disease (severe group) had nAbs with binding and neutralization titers higher than non-severe group. Severe group appeared a rapid increase of lymphocytes and a high proportion of circulating CXCR3+ Tfh cells. Interestingly, the later were spike-specific and positively correlated with SARS-CoV-2 nAb titers. All subjects had no autoimmunity. Our findings provide novel insights into nAb responses in COVID-19 convalescents and facilitate treatment and vaccine development for SARS-CoV-2 infection.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
638 papers in training set
Top 0.5%
18.2%
2
Cell Reports Medicine
153 papers in training set
Top 0.1%
7.7%
3
Clinical & Translational Immunology
22 papers in training set
Top 0.1%
6.6%
4
JCI Insight
277 papers in training set
Top 1%
5.4%
5
PLOS Pathogens
820 papers in training set
Top 4%
4.2%
6
Scientific Reports
3612 papers in training set
Top 24%
4.2%
7
Cellular & Molecular Immunology
14 papers in training set
Top 0.1%
4.0%
50% of probability mass above
8
eBioMedicine
183 papers in training set
Top 0.8%
3.4%
9
Nature Communications
5641 papers in training set
Top 36%
3.2%
10
PLOS ONE
5266 papers in training set
Top 43%
2.3%
11
Frontiers in Medicine
120 papers in training set
Top 1%
2.3%
12
Journal of Clinical Immunology
14 papers in training set
Top 0.1%
2.3%
13
The Journal of Immunology
166 papers in training set
Top 1%
2.1%
14
Clinical Immunology
21 papers in training set
Top 0.2%
1.7%
15
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.3%
1.7%
16
The Journal of Infectious Diseases
202 papers in training set
Top 2%
1.7%
17
Microbiology Spectrum
469 papers in training set
Top 7%
1.7%
18
iScience
1154 papers in training set
Top 18%
1.7%
19
eLife
5828 papers in training set
Top 51%
1.7%
20
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.7%
21
Clinical Infectious Diseases
235 papers in training set
Top 2%
1.7%
22
Cell Reports
1498 papers in training set
Top 22%
1.3%
23
Communications Medicine
113 papers in training set
Top 4%
1.1%
24
BMC Infectious Diseases
133 papers in training set
Top 4%
1.0%
25
Viruses
332 papers in training set
Top 4%
1.0%
26
Annals of the Rheumatic Diseases
36 papers in training set
Top 0.4%
1.0%
27
European Journal of Immunology
60 papers in training set
Top 1%
1.0%
28
BMC Medicine
176 papers in training set
Top 5%
0.8%
29
Journal of Medical Virology
140 papers in training set
Top 4%
0.6%
30
Immunity
67 papers in training set
Top 2%
0.6%